Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform. News about RenovoRx often highlights progress in both its commercial activities and its clinical development programs.
Investors following RNXT news can expect regular updates on the commercialization of RenovoCath as a stand‑alone targeted drug‑delivery device, including adoption trends among cancer centers, repeat purchase orders, and the expansion of institutions approved to purchase the device. Company announcements also describe physician interest and growing clinical demand for localized, arterial drug‑delivery approaches in solid tumors.
Another major news theme is RenovoRx’s ongoing Phase III TIGeR‑PaC trial, which evaluates intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer. Press releases cover clinical milestones, pharmacokinetic and pharmacodynamic sub‑study results, and abstract acceptances and presentations at scientific meetings such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
RenovoRx news also includes updates on its post‑marketing observational registry study collecting real‑world safety and survival data in solid tumors, as well as its support of investigator‑initiated trials in borderline resectable and metastatic or oligometastatic pancreatic cancer. In addition, the company reports on corporate developments such as Scientific Advisory Board appointments, participation in investor and industry conferences, and capital markets activities disclosed in SEC filings.
For readers tracking RNXT, this news stream provides ongoing insight into how RenovoRx is advancing its TAMP platform, expanding RenovoCath’s commercial footprint, and generating clinical evidence around its drug‑device combination candidate IAG.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RenovoRx, a biopharmaceutical company focused on targeted drug delivery for locally advanced pancreatic cancer, announced the appointment of Dr. Robert J. Spiegel to its Board of Directors as of April 25, 2023. With over 40 years in the biopharmaceutical sector, Dr. Spiegel has been instrumental in more than 30 FDA drug approvals, including significant cancer therapies. His leadership is expected to drive discussions with the FDA to expedite progress with RenovoGem™, currently in a Phase III trial for LAPC. RenovoRx's innovative drug delivery platform, RenovoTAMP™, aims to improve treatment outcomes while minimizing side effects. The company holds multiple patents and has received Orphan Drug Designation for its therapies. CEO Shaun Bagai emphasized ongoing trial enrollment and regulatory engagement as part of the company’s growth strategy.
RenovoRx, a biopharmaceutical company, presented interim data from its Phase III TIGeR-PaC study at the AACR Annual Meeting. The analysis revealed that patients receiving the RenovoGem therapy for locally advanced pancreatic cancer exhibited a 60% improvement in median overall survival, reaching 16 months compared to 10 months for those on standard chemotherapy (IV gemcitabine and nab-paclitaxel). Additionally, RenovoGem patients experienced over a 65% reduction in adverse events such as nausea and fatigue. The Data Monitoring Committee found the results promising enough to continue the trial, which aims to enroll 114 patients. CEO Shaun Bagai emphasized the therapy's potential to change treatment protocols and enhance patient life quality. The next interim analysis is anticipated in mid to late 2024.